Key Points {#FPar12}
==========

Patients receiving first-line pazopanib for metastatic renal cell carcinoma (mRCC) often undergo dose modifications because of comorbidities or toxicity, but whether reduced-dose pazopanib is as effective as the standard dose in achieving a clinical benefit is unclear.This study may suggest that patients with mRCC who receive a lower dose of first-line pazopanib might not have a meaningful progression-free survival advantage compared with those receiving a standard dose.

Introduction {#Sec1}
============

Agents that target angiogenesis through the vascular endothelial growth factor (VEGF) pathway are the backbone of therapy for metastatic renal cell carcinoma (mRCC) \[[@CR1], [@CR2]\]. Variations in drug levels in patients treated with VEGF receptor (VEGFR) tyrosine kinase inhibitors (TKIs) represent a significant challenge in the treatment of patients with mRCC. Plasma exposure varies according to dose, and correlation is lacking between plasma levels and efficacy in individual patients \[[@CR3], [@CR4]\]. The pharmacokinetics of TKIs have demonstrated significant interindividual variability, which might contribute to the variable clinical response observed in patients receiving these drugs \[[@CR5]\]. As a result, the variability in plasma exposure and clinical efficacy is reflected in the dosing recommendations for these TKIs. In addition, a number of factors affect the efficacy of a drug or treatment regimen in patients with cancer, including patient and tumor characteristics, tumor biology, and systemic exposure to the drug, which may vary because of schedule and/or dosing modifications due to toxicity \[[@CR6]\]. Whether current dosing and schedules for TKIs are optimal in terms of achieving a maximum therapeutic response remains unclear, and a subset of patients will continue to have subtherapeutic drug levels such that progressive disease (PD) during VEGFR TKI therapy might not be a product of resistance to therapy but rather a result of underdosing. First-line pazopanib is one of the standard options for treatment-naïve mRCC \[[@CR2]\], but it is frequently associated with adverse events (AEs) and dose reductions. The most common AEs related to pazopanib include fatigue, nausea, diarrhea, hypertension, anorexia, and hair depigmentation, as well as aspartate transaminase (AST) and alanine transaminase (ALT) elevations \[[@CR2]\]. Liver abnormalities (3.8%), diarrhea (2%), and arterial thrombotic events (2%) are the most common reasons for treatment discontinuation. Toxicity often leads to dose reductions or treatment discontinuation, which might improve tolerability; however, whether a reduced dose is comparable to a standard dose in achieving response or delaying disease progression is unclear. The goal of the present retrospective analysis was to investigate the clinical effect of different therapeutic doses of first-line pazopanib in patients with mRCC.

Materials and Methods {#Sec2}
=====================

Patients and Treatment {#Sec3}
----------------------

This was a single-center retrospective cohort study. Details of consecutive patients with mRCC treated with pazopanib as a first-line targeted therapy between 2011 and 2016 at the Istituto Nazionale Tumori of Milano (Italy), a comprehensive cancer center, were analyzed. Baseline demographics, including comorbidities and treatment duration, were evaluated. After reviewing the therapeutic schedule and dosage, investigators divided patients into three groups: patients who started treatment with the standard oral pazopanib 800 mg daily and continued to receive the same dose throughout the treatment (group 1); patients who switched from oral pazopanib 800 mg daily to oral pazopanib 600 or 400 mg daily because of intolerable toxicity or patient refusal to continue treatment at the same dose (group 2); and frail subjects who started treatment with oral pazopanib 400 mg or 600 mg daily because of a low Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 2 or comorbidities according to local treating clinical practice (group 3).

Data Analysis {#Sec4}
-------------

The primary study outcome was progression-free survival (PFS), defined as the time from initiation of pazopanib therapy to the date of first documented disease progression, loss to follow-up, or death due to any cause, whichever occurred first. Secondary study outcomes included treatment duration, discontinuation rate, and treatment response. Treatment response was assessed using the RECIST (Response Evaluation Criteria in Solid Tumors) version 1.1 criteria \[[@CR7]\], whereas requirements for dose reduction and assessment of toxicity were evaluated according to CTCAE (Common Terminology Criteria for Adverse Events) version 4.0 \[[@CR8]\].

Statistical Analyses {#Sec5}
--------------------

The PFS incidence rate was calculated as the ratio between the number of PFS events and the sum of total PFS time contributed by all patients. Because of the treatment shift to a reduced dose from group 1 to group 2, survival functions were estimated using the Simon--Makuch method. The Cox regression model was used to detect the statistical association and to estimate the hazard ratio (HR). Median follow-up time was estimated using the reverse Kaplan--Meier method. The objective response rate (ORR) was calculated as the percentage of complete and partial treatment response. Baseline covariate distributions and treatment characteristics were summarized using descriptive statistics (median and range for continuous variables; absolute and percentage frequencies for categorical variables). All statistical tests were two-sided. Given the descriptive nature of the study, hypothesis testing was applied qualitatively (i.e., no threshold for statistical significance was defined). Statistical analysis was performed using SAS version 9.2 (SAS Institute Inc., Cary, NC, USA). The Kaplan--Meier curves were plotted using STATA software version 12.1 (StataCorp, College Station, TX, USA).

Results {#Sec6}
=======

From June 2011 to September 2016, a total of 69 patients started treatment with first-line pazopanib; 34 (49%), 19 (28%), and 16 subjects (23%) were evaluated in groups 1, 2, and 3, respectively. The median age at diagnosis was 62 years, and 64% were male. Overall, 13% and 87% of patients were classified as Heng 'good' and 'intermediate' risk, respectively. Patients' baseline characteristics are reported in Table [1](#Tab1){ref-type="table"}. Cardiovascular comorbidities at baseline were observed in ten (29%), six (32%), and 14 (88%) patients in groups 1, 2, and 3, respectively (Table [1](#Tab1){ref-type="table"}).Table 1Patient characteristicsCharacteristicFull dose (*N* = 34)Dose reduction (*N* = 19)Starting dose reduction (*N* = 16)Total patients (*N* = 69)Sex Male27 (79)6 (32)10 (63)43 (62) Female7 (21)13 (68)6 (37)26 (38)Median age (years)62ECOG performance status 027 (79)18 (95)6 (38)51 (74) 16 (18)1 (5)7 (44)14 (20) 21 (3)--3 (19)4 (6)Comorbidities Cardiovascular10 (29)6 (32)14 (88)30 (43) Diabetes mellitus4 (12)2 (11)4 (25)10 (14) Other2 (6)2 (11)2 (13)6 (9)Histology Clear cell34 (100)19 (100)15 (94)68 (99) Non-clear cell----1 (6)1 (1)Nephrectomy Yes32 (94)19 (100)16 (100)67 (97) No2 (6)----2 (3)Heng score Good6 (18)2 (811)2 (13)10 (14) Intermediate27 (79)17 (89)14 (88)58 (84) Poor1 (3)----1 (1)Metastatic sites (*N*) 114 (41)8 (44^a^)7 (44)29 (42) 219 (56)7 (39^a^)6 (38)32 (46) 3--62 (6)3 (17^a^)3 (19)8 (12)Metastatic sites Lymph node14 (41)2 (11^a^)6 (38)22 (32) Bone9 (26)3 (17^a^)2 (13)14 (20) Lung3 (9)7 (39^a^)2 (13)12 (17) Pancreas3 (9)7 (39^a^)2 (13)12 (17) Contralateral kidney1 (3)2 (11^a^)2 (13)5 (7) Liver2 (6)3 (17^a^)2 (13)7 (10) Other^b^7 (21)1 (5)3 (19)11 (16)Data are presented as *N* (%) unless otherwise indicated*ECOG* Eastern Cooperative Oncology Group, *PS* performance status^a^Sites of disease missing for one patient^b^Pleura, brain, skin, adrenal gland

Treatment and Adverse Event Profile {#Sec7}
-----------------------------------

After starting oral pazopanib treatment at the full dose (800 mg daily), 16 patients (84%) reduced the dose to 400 mg daily, and three (16%) reduced the dose to 600 mg daily (overall, 19 patients who were defined as group 2). The most frequent reasons for reducing the dose were grade 2 fatigue (*n* = 2; 11%), mucositis (*n* = 1; 5%), diarrhea (*n* = 1; 5%), nausea (*n* = 3; 16%), neutropenia (*n* = 1; 5%), mucositis (*n* = 1; 5%), hypertransaminasemia (*n* = 3; 16%), and hypertension (*n* = 3; 16%) and grade 3 hypertension (*n* = 7; 37%), hypertransaminasemia (*n* = 4; 21%), and fatigue (*n* = 8; 42%). In total, 34 (56%) patients who started on pazopanib 800 mg daily maintained the full dose of pazopanib. The most frequent toxicities reported among these patients were grade 1 diarrhea (*n* = 5; 33%), fatigue (*n* = 7; 47%), hypertension (*n* = 1; 7%), mucositis (*n* = 1; 7%), and skin rash (*n* = 1; 7%) and grade 2 diarrhea (*n* = 2; 13%), nausea (*n* = 1; 7%), vomiting (*n* = 1; 7%), fatigue (*n* = 2; 13%), and hypertension (*n* = 1; 7%). In group 3, a total of 12 (75%) subjects started treatment at a reduced dose of 400 mg daily, and four (25%) started at 600 mg daily. The most frequent reason for starting treatment at a reduced dose was cardiovascular comorbidity, including uncontrolled hypertension in seven patients (44%), previous acute myocardial infarction in three patients (19%), previous transient ischemic attack in two patients (12.5%), arrhythmias in three patients (19%), and Felty's syndrome in one case, and three of these patients presented with an ECOG PS of 2 (Table [1](#Tab1){ref-type="table"}). The incidence of some grade 3 toxicities commonly associated with pazopanib were fatigue (20% in group 1 vs. 6% in group 2 + 3), hypertension (13% in group 1 vs. 0% in group 2 + 3), and liver function test failure (6% in group 1 vs. 0% in group 2 + 3) (Table [2](#Tab2){ref-type="table"}). Table 2Pazopanib administration and adverse events profileCharacteristicsGroup 1Group 2Group 3TotalPazopanib starting dose (mg/daily) 80053 (77)19 (36)--53 (77) 600----4 (25)4 (6) 400----12 (75)12 (17)Dose reduction (mg/daily) Yes19 (36)19 (36)16 (23)35 (51)  6003 (6)--3 (4)  40016 (30)-- No34 (64)----34 (49)Fatigue Grade 1 and 29 (27)2 (11)9 (56)20 (29) Grade 31 (3)1 (5)1 (6)3 (4)Hypertension Grade 1 and 24 (8)3 (16)2 (12)9 (13) Grade 32----2 (3)Mucositis Grade 1 and 21 (3)1 (5)--2 (3) Grade 3--------Diarrhea Grade 1 and 27 (21)2 (11)--9 (13) Grade 3--3 (16)--3 (4)Nausea Grade 1 and 21 (3)3 (16)7 (44)11 (16) Grade 31 (3)----1 (1)Liver toxicity Grade 1 and 21 (3)3 (16)2 (12)6 (9) Grade 31 (3)----1 (1)Skin rash Grade 1 and 21 (3)----1 (1) Grade 3--------Data are presented as point estimate (95% confidence interval) unless otherwise indicated*NA* not applicable^a^Incidence rate is presented as events per 100 person-months

Treatment Duration and Survival {#Sec8}
-------------------------------

After a median follow-up of 13.9 months (range 0.3--43.8), 27 (39.1%) patients had PD and three (4%) patients had died (total PFS events 30). At the date of last follow-up, 17 (50%), seven (37%), and six (38%) patients were alive and receiving treatment in groups 1, 2, and 3, respectively, whereas 17 (50%), 12 (63%), and ten (62%) patients had discontinued treatment because of PD or toxicity or were lost to follow-up. Patients had been taking pazopanib for a median of 9.6 months (range 0.3--43.8) in group 1, for 13.6 months (range 0.1--29.5) in group 2, and for 18.3 months in group 3. The PFS incidence rate per 100 person-months was 2.5 \[95% confidence interval (CI) 0.6--4.4; HR 1\] in group 1 and 3.9 \[95% CI 0.68--2.98; HR 1.43 (95% CI 0.68--2.98)\] in group 2 + 3 (Table [3](#Tab3){ref-type="table"}). Rates of discontinuation due to PD were 28% (15 patients) in group 1, 42% (eight patients) in group 2, and 44% (seven patients) in group 3. The ORR was 44, 11, and 19% in groups 1, 2, and 3, respectively. When dose-reduction groups 2 and 3 were considered together and defined as a group (2 + 3), the PFS incidence rates were as summarized in Table [3](#Tab3){ref-type="table"}. Median PFS was not reached in group 1 and was 17.9 months (95% CI 7.6--44.8) for group 2 + 3 (Figs. [1](#Fig1){ref-type="fig"}, [2](#Fig2){ref-type="fig"}). Before a PFS event, patients had been taking pazopanib for a median of 9.6 months (range 0.3--43.8) in group 1, for 13.6 months (range 0.1--29.5) in group 2, and for 18.3 months (range 2.1--31.4) in group 3. At the univariate analysis, the dose-reduction group (2 + 3) was associated with less favorable survival (HR 1.43; 95% CI 0.68--2.98; *p* = 0.343) than was group 1. The multivariate analysis confirmed that the worse outcome was associated with dose reduction (HR 1.44; 95% CI 0.69--3.00) for the dose-reduction group (2 + 3), whereas the Heng prognostic score discriminated between a 'good' and an 'intermediate' score (HR 0.66; 95% CI 0.20--2.17; *p* = 0.501) in the overall population analysed. In group 1, three patients experienced complete response (CR), 12 patients experienced partial response (PR), and 11 patients experienced stable disease (SD), with an ORR (CR + PR) of 44%. In group 2, no CRs were reported, whereas two and seven patients achieved PR and SD, respectively, with an ORR of 11%. In group 3, no CRs were seen, whereas three patients reported a PR and four patients reported SD, with an ORR of 19 (Table [4](#Tab4){ref-type="table"}).Table 3Progression-free survival incidence rate and hazard ratio for groups 1 and (2 + 3)GroupIncidence rate^a^Hazard ratio*p* value 12.5 (0.6--4.4)1 (NA)0.343 (2 + 3)3.9 (0--14.3)1.43 (0.68--2.98)Multivariate analysis Group  11 (NA)0.334  (2 + 3)1.44 (0.69--3.00) Heng score  Poor--intermediate1 (NA)0.488  Good0.66 (0.20--2.17)Data are presented as *n* (%) Fig. 1Progression-free survival curves for groups 1 (G1), 2 (G2), and 3 (G3) Fig. 2Progression-free survival curves for group 1 (G1) and groups 2 and 3 combined \[G (2 + 3)\] Table 4Response ratesCharacteristicGroup 1Group 2Group 3TotalResponse rate CR3 (8.8)----3 (4) PR12 (35.3)2 (10.5)3 (18.8)17 (25) SD11 (32.3)7 (36.8)4 (25)22 (32) PD8 (23.5)2 (10.5)3 (18.8)13 (19) NA--1 (5.2)--Present status Alive, on treatment17 (50)7 (37)6 (38)30 (43) Drug discontinued due to death/progressive disease/toxicity/drug holiday17 (50)12 (63)10 (62)39 (57)Data are presented as *n* (%)*CR* complete response, *NA* not available, *PD* progressive disease, *PR* partial response, *SD* stable disease

Discussion {#Sec9}
==========

Pazopanib is a recommended first-line option for the treatment of mRCC \[[@CR9], [@CR10]\]. Retrospective data have shown that an increased median PFS and tumor shrinkage appear in patients with higher plasma trough drug levels (*C* ~min~) \[[@CR11]\]. Therefore, patients with a low *C* ~min~ might benefit from pharmacokinetically guided individualized dosing. Dose reductions to pazopanib 400 mg occurred in 30% of patients with RCC in the phase II study \[[@CR12]\]. The most common AEs leading to dose interruptions or reductions were diarrhea, hypertension, and increased ALT/AST levels \[[@CR12]\]. Results suggest that the frequency of these common AEs could be reduced by decreasing systemic exposure to pazopanib through dose reductions or interruptions. However, interpatient heterogeneity in the metabolism and/or absorption of pazopanib can lead to differences in systemic exposure. Nevertheless, in clinical practice, both comorbidities and AEs might limit the pazopanib dosage and affect therapeutic response. To investigate the greatest benefit, we analyzed the relationship between different pazopanib doses and efficacy. In our study, the majority of patients started on the standard dose of pazopanib 800 mg daily; however, 19 (36%) of these patients required a dose reduction, and 16 (23%) patients started pazopanib on a reduced dose because of comorbidities. On the other hand, 14 (41%), nine (47.4%), and nine (56.3%) patients in groups 1, 2, and 3, respectively, discontinued treatment because of PD or toxicity. The most common AEs observed in our study were fatigue (33.3%), nausea (17.4%), diarrhea (16%), and hypertension (13%), which is consistent with data in the literature \[[@CR2]\]. Treatment duration and toxicity data from real-world experience with sunitinib and sorafenib show that, overall, about half of patients require a dose reduction of sunitinib \[[@CR13]\] and sorafenib \[[@CR14], [@CR15]\] because of toxicity; however, no similar data are yet available for pazopanib. The disease control rate (DCR) in our report (*n* = 20; 29%) is slightly lower than that reported in the literature, but it raised significantly when considering the DCR reported in group 1 (44%). The median PFS (not reported for group 1 and 17.9 months for group 2 + 3) was higher than that reported in other studies \[[@CR9], [@CR10]\], but this might reflect the small sample considered in the dose reduction cohort as well as the clinical management of side effects leading to longer treatment exposure. Moreover, only subjects with clear cell histology and good and intermediate prognosis treated with first-line pazopanib were included in the study as per clinical practice in Italy. At both univariate and multivariate analysis, dose reduction was associated with worse outcomes. These results should be interpreted with great caution because of methodological limits. Moreover, sampling variability was high because of the low number of PFS events collected. Imbalance of other confounders not considered in the multivariate regression model could heavily bias effect estimates. Different PFS assessments between groups and time-varying PFS incidence rates could also bias effect estimates. The lack of a preplanned hypothesis to test, the retrospective nature of the data, the single institution experience, and the small sample size must also be taken into consideration in terms of the reliability and generalizability of this study. In light of this variability and the relationship between systemic exposure and clinical benefit and toxicities, dose adjustments based on plasma concentrations may provide a method to optimize pazopanib therapy by maintaining therapeutically effective blood levels and minimizing AEs. To the best of our knowledge, this is the first study to report outcomes for patients treated with reduced-dose first-line pazopanib and may represent a useful addition to the growing literature on TKIs in mRCC.

Conclusions {#Sec10}
===========

Our data may suggest that patients with mRCC receiving a lower dose of first-line pazopanib might not have a meaningful PFS advantage compared with those receiving a standard dose. These results highlight that the optimal management of treatment-related side effects may eventually lead to proper drug exposure.
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